BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study
Clinical & Experimental Allergy · 2024
DOI: 10.1111/cea.14491 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von Tom Marrs und 22 weiteren Autor:innen. Beteiligte Einrichtung: Children's Allergies, Evelina London, Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Arachis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Palforzia® enables the safe and effective desensitisation of children with peanut allergy. The treatment pathway requires multiple visits for dose escalation, up‐dosing, monitoring of patients taking maintenance therapy and conversion onto daily real‐world peanut consumption. The demand for peanut immunotherapy outstrips current National Health Service (NHS) capacity and requires services to develop a national consensus on how best to offer Palforzia® in a safe and equitable manner. We undertook a Delphi consensus exercise to determine guidance statements for the implementation of Palforzia®‐based immunotherapy in the NHS.
Methods
We undertook focus groups with children and young people who had received peanut immunotherapy to assess what was important for them and their carers. Common themes from patients formed the basis of creating draft statements. A panel of 18 multi‐disciplinary professionals engaged in two rounds of anonymised voting to adapt the statements and score their importance. A final consensus workshop consolidated any variation in comments and scores to develop the final guidance statements.
Results
The panel achieved consensus on 91% (29/32) of guidance statements, demonstrating strong consensus around pragmatic principles for assuring the integrity of consent, safety and conversion from Palforzia® to real‐world peanut products. The greatest amount of feedback was generated from three broad issues; (i) whether eligibility assessment should include compulsory peanut challenges and whether these should be designed to assess the threshold at which patients react to peanut, (ii) the governance processes to best ensure that patients' interests are prioritised and (iii) how to safely transition young people to other services, or discharge them, while they are taking daily peanut.
Conclusions
This consensus highlights the urgent need for the NHS to increase capacity for undertaking diagnostic food challenges as well as developing Palforzia® immunotherapy pathways. The voting panel agreed that families of peanut allergic children should be made aware of immunotherapy, that eligibility assessment should include how co‐morbid conditions are managed and that services should monitor for adverse effects. The finalised statements are now published online for clinical practice in the UK. These guidance statements will be adapted in the coming years as more evidence is published and as the international experience of peanut immunotherapy evolves.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Children's Allergies, Evelina London, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Paediatric Allergy, Department of Women and Children's Health, Faculty of Life Course and Population Sciences, King's College London, Westminster, UK.
- Paediatric Allergy Service, Imperial College NHS Foundation Hospitals, St Mary's Hospital, London, UK.
- NIHR Imperial Biomedical Research Centre, St Mary's Hospital, London, UK.
- Paediatric Department, Sheffield Children's Hospital, Sheffield, UK.
- Paediatric Allergy Department, King's College Hospital, London, UK.
ORCID-Profile: Tom Marrs, Anjali Rampersad, Graham Roberts, Louise Jane Michaelis, Helen A Brough, Helen Smith, Paul J Turner
Zitieren
APA
Marrs, T., Patel, N., Burrell, S., Rampersad, A., Minshall, E., Leech, S., Chandratilleke, D., Dempsey, J., Ludman, S., Roberts, G., Michaelis, L. J., Brough, H. A., Karanam, S., Batt, R., Moulsdale, P., Steifel, G., Tiwana, K., Smith, H., Knight, K., …, & Makwana, N. (2024). BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14491
Vancouver
Marrs T, Patel N, Burrell S, Rampersad A, Minshall E, Leech S, et al. BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14491
BibTeX
@article{Marrs2024,
author = {Marrs, Tom and Patel, Nandinee and Burrell, Sarah and Rampersad, Anjali and Minshall, Eleanor and Leech, Susan and Chandratilleke, Dinusha and Dempsey, Justine and Ludman, Sian and Roberts, Graham and Michaelis, Louise Jane and Brough, Helen A and Karanam, Surendra and Batt, Rebecca and Moulsdale, Phoebe and Steifel, Gary and Tiwana, Kiran and Smith, Helen and Knight, Katherine and Vazquez-Ortiz, Marta and Vyas, Deepan and Turner, Paul J and Makwana, Nick},
title = {BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study},
journal = {Clinical & Experimental Allergy},
year = {2024},
doi = {10.1111/cea.14491}
}
EUVIMED